Atara Biotherapeutics, Inc. (ATRA) Reaches $45.43 After 3.00% Down Move; UnitedHealth Group (UNH) Shorts Down By 3.15%

February 15, 2018 - By Winifred Garcia

The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a huge mover today! The stock decreased 6.05% or $2.925 during the last trading session, reaching $45.425. About 1.17 million shares traded or 42.80% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since February 15, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.The move comes after 9 months negative chart setup for the $1.71B company. It was reported on Feb, 15 by Barchart.com. We have $44.06 PT which if reached, will make NASDAQ:ATRA worth $51.24M less.

UnitedHealth Group (NYSE:UNH) had a decrease of 3.15% in short interest. UNH’s SI was 7.59 million shares in February as released by FINRA. Its down 3.15% from 7.84M shares previously. With 2.80 million avg volume, 3 days are for UnitedHealth Group (NYSE:UNH)’s short sellers to cover UNH’s short positions. The SI to UnitedHealth Group’s float is 0.8%. The stock decreased 2.51% or $5.73 during the last trading session, reaching $223.05. About 1.63 million shares traded. UnitedHealth Group Incorporated (NYSE:UNH) has risen 32.76% since February 15, 2017 and is uptrending. It has outperformed by 16.06% the S&P500.

Among 7 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Atara Biotherapeutics had 21 analyst reports since September 9, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Tuesday, December 15 by JMP Securities. Citigroup downgraded the shares of ATRA in report on Thursday, February 15 to “Sell” rating. The firm earned “Sell” rating on Monday, August 22 by Citigroup. The company was initiated on Friday, September 25 by JMP Securities. Jefferies reinitiated Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Thursday, June 22 with “Buy” rating. Jefferies reinitiated Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Monday, October 24 with “Buy” rating. The firm has “Sell” rating by Citigroup given on Tuesday, December 15. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, November 18. Citigroup upgraded the stock to “Neutral” rating in Wednesday, January 3 report. As per Thursday, August 31, the company rating was maintained by Jefferies.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on March, 8. They expect $-1.14 EPS, down 80.95% or $0.51 from last year’s $-0.63 per share. After $-1.02 actual EPS reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76% negative EPS growth.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.71 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Investors sentiment increased to 1.54 in 2017 Q3. Its up 0.26, from 1.28 in 2017Q2. It is positive, as 8 investors sold Atara Biotherapeutics, Inc. shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported. 12 West Mgmt Lp has invested 0.92% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Credit Suisse Ag reported 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Alyeska Invest Gp Ltd Partnership invested in 174,868 shares or 0.02% of the stock. Barclays Pcl invested in 15,932 shares or 0% of the stock. Alps Advsr Incorporated accumulated 30,095 shares. Millennium Mgmt holds 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) or 21,714 shares. Redmile Gru Ltd holds 2.36% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 2.89 million shares. State Of Wisconsin Invest Board invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Ameritas Invest Prns holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1,810 shares. Tower Rech Limited Com (Trc) owns 1,253 shares. Essex Inv Management Ltd Company stated it has 25,905 shares. Fincl Bank Of America Corp De stated it has 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Rhumbline Advisers owns 31,598 shares. Neuberger Berman Gp Ltd Com reported 0.02% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Fmr Ltd Liability Corporation owns 1.80 million shares for 0% of their portfolio.

Since August 15, 2017, it had 0 buys, and 13 insider sales for $4.45 million activity. MCGRATH JOHN sold 4,200 shares worth $60,102. Haqq Christopher had sold 6,000 shares worth $91,800. Another trade for 48,500 shares valued at $1.68M was made by Ciechanover Isaac E. on Monday, January 22. $140,802 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Soffer Gad on Tuesday, August 15. $16,931 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Gallagher Carol Giltner. Another trade for 3,021 shares valued at $43,291 was sold by Clark Mitchall G..

UnitedHealth Group Incorporated operates as a diversified health and well-being firm in the United States. The company has market cap of $216.15 billion. The companyÂ’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. It has a 20.81 P/E ratio. It also provides services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, ChildrenÂ’s Health Insurance Program, and health care programs; and health services, including commercial health and dental benefits.

Investors sentiment decreased to 0.91 in Q3 2017. Its down 0.11, from 1.02 in 2017Q2. It fall, as 46 investors sold UnitedHealth Group Incorporated shares while 524 reduced holdings. 112 funds opened positions while 408 raised stakes. 810.94 million shares or 0.66% less from 816.36 million shares in 2017Q2 were reported. Garrison Bradford & Assoc Inc holds 16.69% in UnitedHealth Group Incorporated (NYSE:UNH) or 101,826 shares. Fifth Third Commercial Bank accumulated 394,386 shares. Ckw Financial Grp Inc reported 500 shares or 0.02% of all its holdings. Alpha Windward Ltd Liability Corp reported 0.19% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Bbva Compass Financial Bank Inc invested in 28,933 shares. Bancshares Of Ny Mellon has invested 0.62% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Eubel Brady And Suttman Asset Mgmt Inc reported 0.08% stake. Federated Investors Inc Pa holds 265,790 shares or 0.15% of its portfolio. Quadrant Cap Management Ltd Co invested in 17,026 shares or 2.46% of the stock. Copeland Cap Limited Liability Corporation reported 40,588 shares. Atalanta Sosnoff Limited invested in 357,274 shares. Kanawha Lc has 0.06% invested in UnitedHealth Group Incorporated (NYSE:UNH). Gm Advisory Grp reported 0.11% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Bryn Mawr holds 0.09% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH) for 8,324 shares. Connor Clark And Lunn Investment Mgmt Ltd has 0.21% invested in UnitedHealth Group Incorporated (NYSE:UNH) for 178,835 shares.

Among 26 analysts covering UnitedHealth Group (NYSE:UNH), 26 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. UnitedHealth Group had 79 analyst reports since September 2, 2015 according to SRatingsIntel. On Wednesday, October 19 the stock rating was maintained by Mizuho with “Buy”. The firm has “Buy” rating by Argus Research given on Friday, July 22. The stock of UnitedHealth Group Incorporated (NYSE:UNH) earned “Buy” rating by Jefferies on Friday, January 12. The rating was maintained by Deutsche Bank with “Buy” on Thursday, July 13. The rating was maintained by Cantor Fitzgerald on Tuesday, October 17 with “Buy”. The stock of UnitedHealth Group Incorporated (NYSE:UNH) earned “Overweight” rating by Morgan Stanley on Wednesday, September 9. The stock of UnitedHealth Group Incorporated (NYSE:UNH) earned “Buy” rating by Mizuho on Tuesday, July 18. The rating was initiated by Credit Suisse with “Buy” on Friday, November 3. The firm earned “Outperform” rating on Wednesday, December 16 by Credit Suisse. The stock of UnitedHealth Group Incorporated (NYSE:UNH) has “Buy” rating given on Tuesday, July 18 by Oppenheimer.

Since August 21, 2017, it had 0 insider purchases, and 10 sales for $30.30 million activity. $10.02 million worth of UnitedHealth Group Incorporated (NYSE:UNH) was sold by RENFRO LARRY C. Shine Kenneth Irwin had sold 198 shares worth $48,025. $2.38 million worth of stock was sold by HOOPER MICHELE J on Wednesday, January 31. BURKE RICHARD T had sold 20,000 shares worth $4.79M. $2.46M worth of UnitedHealth Group Incorporated (NYSE:UNH) was sold by BALLARD WILLIAM C JR on Tuesday, January 23. Another trade for 5,600 shares valued at $1.12 million was made by WILENSKY GAIL R on Tuesday, September 5. $200,333 worth of UnitedHealth Group Incorporated (NYSE:UNH) shares were sold by ROOS THOMAS E.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: